This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DeNardo, S. J. Articles by Ivkov, R. Search for Related Content PubMed PubMed Citation Articles by DeNardo, S. J. Articles by Ivkov, R.

Development of Tumor Targeting Bioprobes (¹¹¹In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy

Authors' Affiliations: ¹ University of California, Davis, Sacramento, California; ² Triton BioSystems, Inc., Chelmsford, Massachusetts; and ³ Micromod Partikeltechnologie GmbH, Rostock, Germany

Requests for reprints: S.J. DeNardo, Radiodiagnosis and Therapy, 1508 Alhambra Boulevard 3100, Sacramento, CA 95816. Phone: 916-734-3787; Fax: 916-451-2857; E-mail: sjdenardo{at}ucdavis.edu.

Objectives: ¹¹¹In-chimeric L6 (ChL6) monoclonal antibody (mAb)–linked iron oxide nanoparticle (bioprobes) pharmacokinetics, tumor uptake, and the therapeutic effect of inductively heating these bioprobes by externally applied alternating magnetic field (AMF) were studied in athymic mice bearing human breast cancer HBT 3477 xenografts. Tumor cell radioimmunotargeting of the bioprobes and therapeutic and toxic responses were determined.

Methods: Using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide HCl, ¹¹¹In-7,10-tetra-azacyclododecane-N, N',N'',N'''-tetraacetic acid-ChL6 was conjugated to the carboxylated polyethylene glycol on dextran-coated iron oxide 20 nm particles, one to two mAbs per nanoparticle. After magnetic purification and sterile filtration, pharmacokinetics, histopathology, and AMF/bioprobe therapy were done using ¹¹¹In-ChL6 bioprobe doses (20 ng/2.2 mg ChL6/ bioprobe), i.v. with 50 µg ChL6 in athymic mice bearing HBT 3477; a 153 kHz AMF was given 72 hours postinjection for therapy with amplitudes of 1,300, 1,000, or 700 Oe. Weights, blood counts, and tumor size were monitored and compared with control mice receiving nothing, or AMF or bioprobes alone.

Results: ¹¹¹In-ChL6 bioprobe binding in vitro to HBT 3477 cells was 50% to 70% of that of ¹¹¹In-ChL6. At 48 hours, tumor, lung, kidney, and marrow uptakes of the ¹¹¹In-ChL6 bioprobes were not different from that observed in prior studies of ¹¹¹In-ChL6. Significant therapeutic responses from AMF/bioprobe therapy were shown with up to eight times longer mean time to quintuple tumor volume with therapy compared with no treatment (P = 0.0013). Toxicity was only seen in the 1,300 Oe AMF cohort, with 4 of 12 immediate deaths and skin erythema. Electron micrographs showed bioprobes on the surfaces of the HBT 3477 cells of excised tumors and tumor necrosis 24 hours after AMF/bioprobe therapy.

Conclusion: This study shows that mAb-conjugated nanoparticles (bioprobes), when given i.v., escape into the extravascular space and bind to cancer cell membrane antigen, so that bioprobes can be used in concert with externally applied AMF to deliver thermoablative cancer therapy.

This article has been cited by other articles:

				S. J. DeNardo, G. L. DeNardo, A. Natarajan, L. A. Miers, A. R. Foreman, C. Gruettner, G. N. Adamson, and R. Ivkov Thermal Dosimetry Predictive of Efficacy of 111In-ChL6 Nanoparticle AMF-Induced Thermoablative Therapy for Human Breast Cancer in Mice J. Nucl. Med., March 1, 2007; 48(3): 437 - 444. [Abstract] [Full Text] [PDF]

				D. Simberg, T. Duza, J. H. Park, M. Essler, J. Pilch, L. Zhang, A. M. Derfus, M. Yang, R. M. Hoffman, S. Bhatia, et al. Biomimetic amplification of nanoparticle homing to tumors PNAS, January 16, 2007; 104(3): 932 - 936. [Abstract] [Full Text] [PDF]